Find a Clinical Trial

Showing 1 - 6 out of 6

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Mycobacterial disease

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients with PDL-1 of <50%

Non-small cell lung cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Division of Thoracic Surgery

Tufts Medical Center

Learn more

R3R

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Chronic kidney disease

All genders

12+

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

To Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

A Randomized, Open-label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Small cell lung cancer

All genders

18+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

VX19-NEN-801

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin

Chronic kidney disease, Glomerular disease, Kidney diseases, Proteinuria

All genders

12-65

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

Lung CA Dental

Evaluating periodontal health in subjects with lung cancer prior to cancer therapy and monitoring impact of periodontal disease on treatment efficacy and side-effects.

Non-small cell lung cancer

All genders

45+

Recruiting now

Department of Medicine, Division of Hematology/Oncology, Cancer Center

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients with PDL-1 of <50%

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

A Randomized, Open-label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin

Evaluating periodontal health in subjects with lung cancer prior to cancer therapy and monitoring impact of periodontal disease on treatment efficacy and side-effects.